The PHARMED teaching team is composed of experts from various universities, regulatory authorities/agencies, CROs and biotechnology companies


A B C D E F G H I J K F Q L M N O P Q R S T U V W Y Z 


Director Consultancy and Clinical Pharmacology SGS – Health Science

Nariné is a pharmacist with a PhD in Pharmaceutical Sciences with 15 years’ experience in Clinical Research. In her recent function of Director Consultancy and Clinical Pharmacology, she is leading consultancy projects at SGS to support sponsors in development of early phase study design, clinical trial protocol, clinical development plan, investigator brochure as well different type of scientific advice. She provides a clinical pharmacology expertise for ongoing clinical trials as well as a scientific consultancy to clients.


General Manager chez HM3A-VIVACTIS

Dr. Marc Czarka, specialist in pharmaceutical medicine and a member of the Belgian College of Pharmaceutical Medicine, has more than 20 years’ experience in three of the top 15 pharmaceutical companies, in local as well as European assignments. His experience includes medical and pharmaceutical affairs, as well as business development, governmental affairs, communication, and crisis management.

In addition, Dr. Czarka was a visiting faculty member at INSEAD, the world renowned business school, where he received executive education. Dr. Czarka taught innovation and R&D in the pharmaceutical industry to MBA students. He is also a scientific contributor at ULB (Free University Brussels) where his contribution goes to the department of Health Economics at the School of Public Health. He is the current chair of the Belgian INSEAD alumni association’s healthcare club.

Benjamin DIZIER

Director, Biomarker Lead, Immunology Translational Medicine at UCB

  • Responsible for establishing and delivering early and late stage biomarker strategy of UCB FCRn inhibitor in neuroimmunology and haematology rare diseases
  • Responsible for implementation of biomarker strategy to support clinical development in China
  • Development of multiple IVDs and CDx to support UCB neuroimmunology assets (including selection of diagnostic partner, contracting, alliance management, IDE submission, CDRH interactions and ex-US regulatory interactions)
  • Part of UCB Core Team to establish organization in charge of IVD and wearables development
  • Development of innovative surrogate primary endpoint for haematology rare disease
  • Responsible for the biomarker dimension of initiative to redefine neuroimmunology indication to allow innovative clinical development, working with KOL and regulatory agencies
  • Contribution to multiple regulatory agencies meetings and interactions (pre-IND, IND, EMA SA, ODD, Japanese PMDA consultation, Chinese CDE consultation)


field application specialist/subject matter expert life sciences at perkinelmer

Customer-oriented PhD with recognized scientific excellence, demonstrated aptitude to internal, external partners and customers collaboration, business development, team and project management, product management and customer support. Passionate about science & technologies, willing to develop products and company in a work environment of excellence regarding organization and human relationships, with recognition of priority of medium to long term objectives. Keen of learning from others and making other benefit from my experience. 

Jonathan Goole

PhD, Pharmacy, Associated professor at Université libre de Bruxelles

A venir

Denis Gossen

CSO & Clinical Pharmacologist & Co-Founder at Aepodia

Dr Gossen has over 25 years’ experience in pharmaceutical and biotechnological drug development.

He received his PhD in Applied Biomedical Sciences from the Free University of Brussels (ULB, Belgium) and completed postdoctoral research as a Belgian American Educational Foundation Fellow (BAEF) at Tufts Medical Centre / New England Medical Centre (Boston).

Dr Gossen worked at Eli Lilly and UCB Pharma as clinical pharmacologist leading the early clinical development of new molecules, responsible of multiple developments programs from first in man studies to proof of concept studies in various therapeutic areas; development of pharmacodynamic and clinical biomarkers;  involved in the definition and realization of several clinical packages to support new drug application (NDA); involved in line extensions and investigation for new indications/new formulations of registered compounds.

Co-founder of Aepodia in 2006, a niche Clinical Research Organization (CRO), partnering with Pharmaceutical and Biotech Companies for early phase clinical programs. As Chief Scientific Officer advices on scientific and regulatory strategy of potential drug candidates and medical devices, first-in-human studies and proof-of-concept studies in patients. Established collaborations with multiple Pharma and Biotech companies in Europe, US, Japan, India.

Since 2021, works as independent consultant.


Director Programme Sante Jouve / Fondateur ETHIK-IA

David Gruson est diplômé de l’Institut d’études politiques (IEP) de Paris et de l’École nationale de la santé publique (ENSP).

Il a commencé sa carrière de directeur d’hôpital à l’Assistance publique-hôpitaux de Paris (AP-HP) en tant que directeur adjoint de l’hôpital Bicêtre (Le Kremlin-Bicêtre, Val-de-Marne), où il a contribué à la création de la direction du service au public (avril 2002-janvier 2004).

Il est entré ensuite à l’ENA. À sa sortie en 2006, il a été nommé auditeur de seconde classe à la Cour des comptes puis conseiller référendaire en juin 2009.

En mars 2009, il a été rapporteur auprès de la commission de concertation sur la politique de la jeunesse. D’avril 2010 à avril 2012, il a été conseiller technique chargé de la santé, du handicap et de la prise en charge de la dépendance au cabinet de l’ancien Premier ministre François Fillon.

David Gruson a été nommé directeur général du CHU de La Réunion en avril 2012, avant d’occuper le poste de délégué général de la FHF entre 2016 et 2017. En 2019, il a rejoint l’entreprise française de services numériques (ESN) Jouve en tant que directeur de programme santé.

En 2018, il a cofondé l’initiative académique et citoyenne Ethik-IA qui défend une “régulation positive” de l’intelligence artificielle et de la robotisation en santé, notamment dans le cadre des états généraux de la bioéthique.

Il est également auteur et coordonnateur de plusieurs ouvrages relatifs à l’IA.

“S.A.R.R.A.” (2018) est son premier roman ainsi que le tout premier polar bioéthique.


Medical Director, Clinical Development Physician at UCB

Medical professional with extensive experience in the research and development of a specialist product portfolio within the pharmaceutical industry.
Strong communicator with the ability to lead and train key stakeholders in multi-product areas, providing clinical and scientific support.
Resilient and commercially astute business leader with the ability to mentor, manage and lead diverse teams to produce outstanding results.


Solutions principal

Define best practices and influence the process improvement in the use of Algorithmic, AI and Advanced Big Data Analytics.
Explore current and emerging technologies to evaluate new opportunities and possibilities. Support the development of both bespoke and standardized analytic offerings across multiple industries. Support the pre-sales activities.
Lead multi-disciplinary teams of scientists (local, nearshore and offshore). Provide the technical direction required to resolve complex issues in order to ensure the on-time delivery of solutions that meet goals and customer expectations.
Leverage industry and domain expertise to solve real-world problems. Design and develop Descriptive, Predictive, and Prescriptive, algorithms, Proof-of-Concept solutions and prototypes in the field of Data Science.z


Co-founder - chief scientific officer at inhatarget therapeutics

I hold a master’s degree in pharmaceutical and biomedical sciences (Université libre de Bruxelles (ULB) 2010) and obtained a PhD degree (ULB, 2016) for research completed in the Laboratory of Pharmaceutics and Biopharmaceutics. I have been the researcher in charge of the inhatarget spin-off project since 2015.

I specialize in drug formulations for inhalation, especially dry powders (e.g. advanced drug delivery systems, controlled-release formulations, carrier-based and carrier-free formulations, particle engineering, nanomedicine) and preclinical development (analytical development, in vitro and in vivo studies, animal models). I co-developed the first two InhaTarget Therapeutics technologies, related to inhaled anticancer chemotherapy and I am inventor of the three patent families exploited by InhaTarget Therapeutics.

I am responsible for all R&D aspects at InhaTarget Therapeutics, including:

– R&D management (proprietary products and research collaboration contracts),
– Innovation strategy,

– Scientific partnership (pharmaceutical companies, universities, academic labs),
– Scientific communication. 


Senior Director, Head of Investigative Toxicology at UCB

Ph.D. in Physiology & Pharmacology 1990, from the University of Montpellier, France. 

Following a post-doc at UCSF, Jean-Pierre Valentin joined the Pierre Fabre Research Centre (1992-98) where he contributed to the discovery and progression into development of 3 candidate drugs. 

He joined AstraZeneca to build from inception, develop and lead the Department of Safety Pharmacology where he contributed to the safety evaluation of ~200 candidate drugs across a wide range of therapy areas, leading to the development and successful registration of several marketed products. 

In February 2014 he joined UCB-Biopharma as Senior Director Head of Investigative Toxicology, based in Belgium.

 Jean-Pierre is a member of several scientific societies; Past President of the Safety Pharmacology Society; co-chair of the HESI subcommittee on QT/Arrhythmia, and the ABPI-NC3Rs-Animal Model Framework and he is representing the EFPIA on the ICHE14-S7B.

 He is involved in training and education programs and is author/co-author of several patents and >180 peer review publications and book chapters.













A venir